The purpose of this legislation, known as the Biotech Investment National Security Act of 2026, is to update and strengthen the United States' approach to managing risks associated with biotechnology investments, particularly those involving China. The main objective is to prevent U.S. capital and intellectual property from being used to enhance China's capabilities in biotechnology, which could pose national security risks. Key provisions of the legislation include redefining what constitutes "prohibited technology" and "notifiable technology" under the Defense Production Act.